Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Sanofi and Owkin announced an expanded multi-year partnership to develop AI-powered biopharma agents for drug discovery and development. The agreement includes a five-year license for Owkin's K Pro AI Scientist platform, which combines multimodal patient data with biological AI systems. This builds on their existing 2021 collaboration focused on oncology and immunology research.